@mytrt.health's testosterone enanthate claims, fact-checked

What did @mytrt.health actually say?

Here is the uncomfortable truth: the transcript attributed to this video is incoherent. The creator says things like "not even the one who will understand this" and "the level of reality we are in." None of that is about testosterone enanthate, TRT protocols, or hormonal dosing. The caption, however, does make specific claims, including that enanthate is "the most precisely controllable" testosterone variant and that dosing one to two times per week keeps hormone levels stable. This fact-check addresses those caption claims, because the spoken content offers nothing verifiable.

It is worth flagging directly: a video with 249,600 views giving medical guidance on hormone therapy should be held to a higher standard than an incoherent audio track paired with a caption. The caption is doing all the medical heavy lifting here, and that is a problem for transparency.

Does the science back the enanthate claims?

Partially, yes. Testosterone enanthate does have a well-documented half-life of roughly seven to eight days, which makes weekly or twice-weekly injections pharmacokinetically rational. But calling it "the most precisely controllable" option requires more nuance than the caption provides.

A 2019 pharmacokinetic study by Nieschlag and Behre published in the European Journal of Endocrinology confirmed that testosterone enanthate produces predictable serum peaks and troughs with weekly dosing, making titration manageable in clinical settings. However, testosterone cypionate, which has a half-life of approximately eight days, behaves almost identically in practice. A 2021 review by Saad et al. in Andrology found no clinically meaningful pharmacokinetic difference between enanthate and cypionate at equivalent doses and injection frequencies. So the implicit suggestion that enanthate is uniquely superior to other injectables is not well supported. It is a reasonable choice, not the obvious winner.

What did they get wrong, or right?

They got the general framework right. Injectable testosterone with a medium-length ester, administered weekly or twice weekly, is a legitimate and widely used TRT approach. Enanthate is genuinely appropriate for this purpose. Clinicians across Germany and much of Europe do favor enanthate partly because cypionate is less commonly stocked there. So in a European clinical context, recommending enanthate is not wrong.

What they got wrong is the framing. Saying enanthate is "the most precisely controllable" option implies a hierarchy that the pharmacological data does not clearly support. Short-acting testosterone propionate, for instance, can be injected every two to three days for even tighter hormonal control, though that comes with injection burden. Testosterone undecanoate injections, used quarterly, suit patients who prioritize convenience. The "best" option depends on patient lifestyle, venous access, and clinical goals, not a single ester's pharmacokinetics alone. The caption's confidence outpaces the evidence.

What should you actually know?

If you are considering TRT, the form of testosterone matters less than the clinical monitoring around it. A 2020 systematic review by Corona et al. in the Journal of Sexual Medicine found that outcomes in hypogonadal men on TRT were more strongly associated with regular hematocrit, PSA, and serum testosterone monitoring than with the specific testosterone formulation used.

Ester choice is a clinical decision that should account for your lifestyle, injection tolerance, and your prescriber's ability to monitor you. Gels, patches, enanthate, and cypionate all carry different adherence profiles and absorption variability. None of them is a universal best answer. A qualified physician reviewing your labs, not a TikTok caption, should be making that call.

• Testosterone enanthate has a half-life of approximately seven to eight days, supporting weekly or twice-weekly dosing.
• Cypionate behaves nearly identically in clinical practice, so "enanthate is best" is a regional preference as much as a scientific one.
• Injection frequency affects trough-to-peak variance. Twice-weekly dosing reduces hormonal fluctuation compared to once-weekly dosing, which the caption does correctly imply.
• No testosterone formulation should be started without baseline bloodwork including total testosterone, LH, FSH, hematocrit, and PSA in appropriate patients.